Boston Scientific reports strong financial growth for Q4 2025 and plans strategic acquisitions to enhance its innovative medical technology portfolio.

Target Overview

Boston Scientific, a leading global medical technology company, has reported impressive financial results for the fourth quarter of 2025, achieving net sales of $5.286 billion. This marks a notable growth of 15.9% on a reported basis and 12.7% on an organic basis compared to the same period last year. Growth was evident across all reportable segments, with MedSurg and Cardiovascular showing organic growth rates of 6.5% and 16.1%, respectively.

Throughout the entire year of 2025, Boston Scientific generated net sales amounting to $20.074 billion, reflecting a reported growth of 19.9% and an organic growth of 15.8%. The company's success is attributed to its commitment to innovation and performance, as highlighted by CEO Mike Mahoney, who emphasized the positive impact on patient lives and ongoing growth prospects.

Industry Overview in the Specific Country

The medical technology industry in the United States is characterized by rapid innovation and a strong emphasis on quality improvement and cost reduction. With increasing health